These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 31855323)
1. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study. van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745 [TBL] [Abstract][Full Text] [Related]
3. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN; Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087 [TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis. Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V; Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378 [TBL] [Abstract][Full Text] [Related]
6. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. Walensky RP; Jacobsen MM; Bekker LG; Parker RA; Wood R; Resch SC; Horstman NK; Freedberg KA; Paltiel AD J Infect Dis; 2016 May; 213(10):1523-31. PubMed ID: 26681778 [TBL] [Abstract][Full Text] [Related]
7. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603 [TBL] [Abstract][Full Text] [Related]
8. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention. Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240 [TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. Price JT; Wheeler SB; Stranix-Chibanda L; Hosek SG; Watts DH; Siberry GK; Spiegel HM; Stringer JS; Chi BH J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 2(Suppl 2):S145-53. PubMed ID: 27355502 [TBL] [Abstract][Full Text] [Related]
11. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand. Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559 [TBL] [Abstract][Full Text] [Related]
12. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. Marshall BDL; Goedel WC; King MRF; Singleton A; Durham DP; Chan PA; Townsend JP; Galvani AP Lancet HIV; 2018 Sep; 5(9):e498-e505. PubMed ID: 29908917 [TBL] [Abstract][Full Text] [Related]
13. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. van de Vijver DAMC; Richter AK; Boucher CAB; Gunsenheimer-Bartmeyer B; Kollan C; Nichols BE; Spinner CD; Wasem J; Schewe K; Neumann A Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782266 [TBL] [Abstract][Full Text] [Related]
15. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa? Verguet S; Stalcup M; Walsh JA Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819 [TBL] [Abstract][Full Text] [Related]
16. Impact and cost-effectiveness of the national scale-up of HIV pre-exposure prophylaxis among female sex workers in South Africa: a modelling analysis. Stone J; Bothma R; Gomez GB; Eakle R; Mukandavire C; Subedar H; Fraser H; Boily MC; Schwartz S; Coetzee J; Otwombe K; Milovanovic M; Baral S; Johnson LF; Venter WDF; Rees H; Vickerman P J Int AIDS Soc; 2023 Feb; 26(2):e26063. PubMed ID: 36807874 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348 [TBL] [Abstract][Full Text] [Related]
18. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel. Ginsberg GM; Chemtob D BMC Public Health; 2020 Feb; 20(1):271. PubMed ID: 32103750 [TBL] [Abstract][Full Text] [Related]
19. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. Gomez GB; Borquez A; Caceres CF; Segura ER; Grant RM; Garnett GP; Hallett TB PLoS Med; 2012; 9(10):e1001323. PubMed ID: 23055836 [TBL] [Abstract][Full Text] [Related]
20. Impact along the HIV pre-exposure prophylaxis "cascade of prevention" in western Kenya: a mathematical modelling study. Bershteyn A; Sharma M; Akullian AN; Peebles K; Sarkar S; Braithwaite RS; Mudimu E J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25527. PubMed ID: 32602669 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]